| Identification | Back Directory | [Name]
CAY10722 | [CAS]
388086-13-3 | [Synonyms]
CAY10722
CAY10722,CAY-10722
N-[2-(2,4-Dichlorophenyl)-5-benzoxazolyl]benzeneacetamide | [Molecular Formula]
C21H14Cl2N2O2 | [MDL Number]
MFCD01839641 | [MOL File]
388086-13-3.mol | [Molecular Weight]
397.25 |
| Chemical Properties | Back Directory | [Boiling point ]
598.7±50.0 °C(Predicted) | [density ]
1.406±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: Slightly soluble | [form ]
A crystalline solid | [pka]
13.04±0.43(Predicted) |
| Hazard Information | Back Directory | [Description]
CAY10722 is an inhibitor of sirtuin 3 (SIRT3), a class III HDAC (71% inhibition at 200 μM).1 SIRT3 is involved in modulating metabolic homeostasis as a NAD+-dependent protein deacetylase in the mitochondria. SIRT3 functions as either an oncogene or tumor suppressor, depending on cancer cell type.2,3 High SIRT3 expression in patient-derived esophageal cancer tissues is associated with shorter survival and, in mice, downregulation leads to a lower tumor load.4 In contrast, low SIRT3 expression in patient-derived breast cancer cells is correlated with shorter survival.5
| [Uses]
SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma[1]. | [IC 50]
SIRT1; SIRT2; SIRT3 | [storage]
Store at -20°C | [References]
1. Salo, H.S., Latinen, T., Poso, A., et al. Identification of novel SIRT3 inhibitor scaffolds by virtual screening Bioorg. Med. Chem. Lett. 23(10),2990-2995(2013).
2. Chen, Y., Fu, L., Wen, X., et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer Cell Death Dis. 5(e1047),1-7(2014).
3. Xiong, Y., Wang, M., Zhao, J., et al. Sirtuin 3: A Janus face in cancer (Review) Int. J. Oncol. 49(6),2227-2235(2016).
4. Zhao, Y., Yang, H., Wang, X., et al. Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer Ann. Diagn. Pathol. 17(6),483-485(2013).
5. Desouki, M.M., Doubinskaia, I., Gius, D., et al. Decreased mitochondrial SIRT3 expression is potential molecular biomarker associated with poor outcome in breast cancer Hum. Pathol. 45(5),1071–1077(2014). |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|